看一下那个临床试验的key inclusions/exclusion’s criteria 吧：https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf Eligible participants were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI > 25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Participants with COVID-19 symptom onset of ≤ 5 days were included in the study. The study excluded individuals with a history of prior COVID-19 infection or vaccination.
看一下那个临床试验的key inclusions/exclusion’s criteria 吧：https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf Eligible participants were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI > 25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Participants with COVID-19 symptom onset of ≤ 5 days were included in the study. The study excluded individuals with a history of prior COVID-19 infection or vaccination. Rutang48 发表于 2022-12-28 17:27
降压药 与辉瑞新药可一同安全应用的降压药： 氢氯噻嗪 Hydroflumethiazide 点评：虽然安全，但这个药作为降压药而单独应用的情况比较少。 应用辉瑞新药时，需要调整剂量或暂停用药的降压药： 氨氯地平 Amlodipine 点评：辉瑞新药，使氨氯地平浓度加倍也就是相当于剂量加倍。 尼福地平 Nifedipine 非洛地平 Felodipine 地尔硫卓 Diltiazem 维拉帕米 Verapamil 多沙唑嗪 Doxazosin 点评：对五大类降压药的集中表述不好，在下面的“心衰药物”部分，还要涉及其它降压药。 心衰治疗药和部分降压药 与辉瑞新药可一同安全应用的降压药： 转换酶抑制剂（各种带“普利”两个字或者结尾带了“Pril”的药物） 坎地沙坦 Candesartan 奥美沙坦 Olmesartan 替米沙坦 Telmisartan 螺内酯 Spironolactone 恩格列净 Empagliflozin 达格列净 Dapagliflozin 卡格列净 Canagliflozin 夫拉塞米 Furosemide 托拉塞米 Torsemide 美托拉宗 Metolazone 氯噻酮 Chlorthalidone 点评：安全的药物比较多，其中不少也是降压药 应用辉瑞新药时，需要调整剂量或暂停用药的降压药： 厄贝沙坦 Irbesartan 点评：辉瑞新药使厄贝沙坦的浓度降低，降压效果下降。 氯沙坦 Losartan 缬沙坦 Valsartan 沙库巴曲/缬沙坦 Sacubitril/valsartan 点评：辉瑞新药使上述三个心衰/降压药的浓度增加，需要在医生的指导下调整剂量或换用其它更全的药物。 地高辛 Digoxin 点评：辉瑞新药使地高辛的浓度增加，地高辛的安全窗口很小，需要在医生的指导下调整剂量。 用辉瑞新药时，不能用的药： 依普利酮 Eplerenone 点评：因为克服螺内酯致男性乳腺发育的副作用，依普利酮是螺内酯的替代药，但辉瑞新药禁忌和依普利酮合用，在用辉瑞新药期间，可回到螺内酯几天。
感谢楼主！很及时，很有用！
Mark
果然 估计做临床试验的时候把有基础病的都排除了
不懂什么叫双盲实验就别自作聪明了。没人把刀架在老人脖子上逼着他们吃辉瑞
谢谢。
楼主好人一生平安！
想起当初gilead那个，被大妈们夸成啥了，最后治了个寂寞
层主说的是对的，双盲前已经把不符合条件的人群排除了。
看一下那个临床试验的key inclusions/exclusion’s criteria 吧：https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf
Eligible participants were 18 years of age and older with at least 1 of the following risk factors for progression to severe disease: diabetes, overweight (BMI > 25), chronic lung disease (including asthma), chronic kidney disease, current smoker, immunosuppressive disease or immunosuppressive treatment, cardiovascular disease, hypertension, sickle cell disease, neurodevelopmental disorders, active cancer, medically-related technological dependence, or were 60 years of age and older regardless of comorbidities. Participants with COVID-19 symptom onset of ≤ 5 days were included in the study. The study excluded individuals with a history of prior COVID-19 infection or vaccination.
我妈得的时候幸亏没吃 😓 她有高血压 家庭医生也没说 😓
这。。。这不是说有基础病的才能入组吗？
啊，知道了，你是反驳上一个层主。
这玩意儿，爱信不信呗。
是啊，这里不是说参与者要有以下至少一种基础病吗？我理解错了吗？
Thanks for sharing
这个我也不太清楚，可能得问一下给你家人开这个药的医生？